Andrew D. Badley

10.3k total citations
195 papers, 6.6k citations indexed

About

Andrew D. Badley is a scholar working on Infectious Diseases, Virology and Immunology. According to data from OpenAlex, Andrew D. Badley has authored 195 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Infectious Diseases, 90 papers in Virology and 57 papers in Immunology. Recurrent topics in Andrew D. Badley's work include HIV Research and Treatment (90 papers), HIV/AIDS drug development and treatment (46 papers) and Immune Cell Function and Interaction (41 papers). Andrew D. Badley is often cited by papers focused on HIV Research and Treatment (90 papers), HIV/AIDS drug development and treatment (46 papers) and Immune Cell Function and Interaction (41 papers). Andrew D. Badley collaborates with scholars based in United States, Canada and France. Andrew D. Badley's co-authors include David H. Lynch, Nathan W. Cummins, Carlos V. Payá, Gary D. Bren, Julian J. Lum, André A. Pilon, Paul J. Leibson, C. V. Paya, Alan Landay and David H. Dockrell and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Andrew D. Badley

187 papers receiving 6.5k citations

Peers

Countries citing papers authored by Andrew D. Badley

Since Specialization

Citations

This map shows the geographic impact of Andrew D. Badley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew D. Badley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew D. Badley more than expected).

Fields of papers citing papers by Andrew D. Badley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew D. Badley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew D. Badley. The network helps show where Andrew D. Badley may publish in the future.

Co-authorship network of co-authors of Andrew D. Badley

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew D. Badley. A scholar is included among the top collaborators of Andrew D. Badley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew D. Badley. Andrew D. Badley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In Vitro Activity of Nisin A Against Staphylococci Isolated from Periprosthetic Joint Infection 2025 ·Antibiotics ·Melissa J. Karau, (unknown), Andrew D. Badley, Nicholas A. Bedard, (unknown), Robin Patel	0
2	Dynamic modulation of the non-canonical NF-κB signaling pathway for HIV shock and kill 2024 ·Frontiers in Cellular and Infection Microbiology ·(unknown), (unknown), Andrew D. Badley	3
3	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19 2022 ·PNAS Nexus ·Arjun Puranik, Patrick J. Lenehan, John C. O’Horo, Colin Pawlowski, Michiel J.M. Niesen, Abinash Virk, Melanie D. Swift, Walter K. Kremers, AJ Venkatakrishnan, (unknown), Holly L. Geyer, Leigh L. Speicher, Venky Soundararajan, Andrew D. Badley	8
4	SARS-CoV-2 and influenza coinfection throughout the COVID-19 pandemic: an assessment of coinfection rates, cohort characteristics, and clinical outcomes 2022 ·PNAS Nexus ·Colin Pawlowski, Eli Silvert, John C. O’Horo, Patrick J. Lenehan, Douglas W. Challener, (unknown), (unknown), Jason Ross, Leigh L. Speicher, Holly L. Geyer, (unknown), Andrew D. Badley, Venky Soundararajan	11
5	Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19 2021 ·EClinicalMedicine ·Raymund R. Razonable, Colin Pawlowski, John C. O’Horo, Lori L. Arndt, Richard Arndt, Dennis M. Bierle, (unknown), Sara N. Hanson, (unknown), Patrick J. Lenehan, Arjun Puranik, Maria Teresa Seville, Leigh L. Speicher, Sidna M. Tulledge‐Scheitel, AJ Venkatakrishnan, Caroline G. Wilker, Andrew D. Badley, Ravindra Ganesh	97
6	Vaccination Safety 2021 ·Mayo Clinic Proceedings ·Aditya Shah, Douglas W. Challener, John C. O’Horo, Andrew D. Badley	1
7	Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19 2021 ·Journal of Clinical Investigation ·Ravindra Ganesh, Colin Pawlowski, John C. O’Horo, Lori L. Arndt, Richard Arndt, Sarah Bell, Dennis M. Bierle, (unknown), Sara N. Hanson, (unknown), Jennifer J. Larsen, Patrick J. Lenehan, Robert Orenstein, Arjun Puranik, Leigh L. Speicher, Sidna M. Tulledge‐Scheitel, AJ Venkatakrishnan, Caroline G. Wilker, Andrew D. Badley, Raymund R. Razonable	36
8	FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system 2021 ·Med ·Colin Pawlowski, Patrick J. Lenehan, Arjun Puranik, (unknown), AJ Venkatakrishnan, Michiel J.M. Niesen, John C. O’Horo, Abinash Virk, Melanie D. Swift, Andrew D. Badley, John Halamka, Venky Soundararajan	112
9	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells 2020 ·Clinical Cancer Research ·(unknown), (unknown), Rondell P. Graham, Nathan W. Cummins, (unknown), Enrique Garcia-Rivera, J. Anderson, Sekar Natesampillai, (unknown), (unknown), Zilin Nie, Thomas D.Y. Chung, Richard Buick, Andrew L. Feldman, Rebecca L. King, Anne J. Novak, Stephen M. Ansell, Saad S. Kenderian, Andrew D. Badley	5
10	Research Response to SARS-CoV-2/COVID-19 2020 ·Mayo Clinic Proceedings ·Charles D. Burger, (unknown), Robert Orenstein, Jon O. Ebbert, Paschalis Vergidis, Andrew D. Badley	4
11	Mechanisms of Human Immunodeficiency Virus-Associated Lymphocyte Regulated Cell Death 2019 ·AIDS Research and Human Retroviruses ·(unknown), Andrew D. Badley, Nathan W. Cummins	15
12	HIV gp120 Induces, NF-κB Dependent, HIV Replication that Requires Procaspase 8 2009 ·PLoS ONE ·Gary D. Bren, Sergey A. Trushin, (unknown), Brett D. Shepard, Andrew D. Badley	18
13	The TRAIL to Viral Pathogenesis: The Good, the Bad and the Ugly 2009 ·Current Molecular Medicine ·Nathan W. Cummins, Andrew D. Badley	46
14	Beneficial Effect of TRAIL on HIV Burden, without Detectable Immune Consequences 2008 ·PLoS ONE ·Brett D. Shepard, (unknown), David McNamara, Andrea Foli, Stacey A. Rizza, Roshini S. Abraham, Keith L. Knutson, Peter J. Wettstein, Franco Lori, Andrew D. Badley	10
15	Short Communication: HIV VprR77Q Mutation Does Not Influence Clinical Response of Individuals Initiating Highly Active Antiretroviral Therapy 2006 ·AIDS Research and Human Retroviruses ·Celia Chui, Peter K. Cheung, Chanson J. Brumme, Theresa Mo, Zabrina L. Brumme, Julio Montaner, Andrew D. Badley, P. Richard Harrigan	12
16	Elimination of Senescent Neutrophils by TNF-Related Apoptosis-Inducing Ligand 2005 ·The Journal of Immunology ·Julian J. Lum, Gary D. Bren, Rebecca F. McClure, Andrew D. Badley	60
17	Increased thymic output in HIV-negative patients after antiretroviral therapy 2005 ·AIDS ·Daniel B. Graham, Michael P. Bell, Catherine J. Huntoon, Joel Weaver, (unknown), Andrew D. Badley, D J McKean	4
18	Resistance to Apoptosis: Mechanism for the Development of HIV Reservoirs 2003 ·Current HIV Research ·Julian J. Lum, Andrew D. Badley	22
19	In vivo analysis of Fas/FasL interactions in HIV-infected patients. 1998 ·Journal of Clinical Investigation ·Andrew D. Badley, David H. Dockrell, (unknown), Steve Ziesmer, Alan Landay, Michael M. Lederman, Elizabeth Connick, Harold A. Kessler, Daniel R. Kuritzkes, David H. Lynch, Patrick C. Roche, H Yagita, C. V. Paya	137
20	The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection. 1998 ·Journal of Clinical Investigation ·David H. Dockrell, Andrew D. Badley, Jorge Villacian, Carrie J. Heppelmann, (unknown), Steve Ziesmer, H Yagita, David H. Lynch, Patrick C. Roche, Paul J. Leibson, C. V. Paya	110

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact